Virpax Pharmaceuticals Stock Z Score

VRPX Stock  USD 0.30  0.01  3.23%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Virpax Pharmaceuticals Piotroski F Score and Virpax Pharmaceuticals Valuation analysis.
For more information on how to buy Virpax Stock please use our How to Invest in Virpax Pharmaceuticals guide.
  
Change In Working Capital is likely to rise to about 4.4 M in 2025, whereas Net Invested Capital is likely to drop slightly above 2.1 M in 2025. At this time, Virpax Pharmaceuticals' Net Interest Income is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 525.3 K in 2025, whereas Interest Expense is likely to drop slightly above 126.5 K in 2025.

Virpax Pharmaceuticals Company Z Score Analysis

Virpax Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Virpax Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Virpax Pharmaceuticals is extremely important. It helps to project a fair market value of Virpax Stock properly, considering its historical fundamentals such as Z Score. Since Virpax Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Virpax Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Virpax Pharmaceuticals' interrelated accounts and indicators.
0.960.78-1.0-0.560.450.280.960.021.00.750.960.020.74-0.72-0.21-0.21
0.960.59-0.97-0.330.540.031.0-0.080.960.871.0-0.080.86-0.540.020.02
0.780.59-0.75-0.940.140.70.570.130.780.320.590.130.3-0.83-0.61-0.61
-1.0-0.97-0.750.53-0.48-0.24-0.970.02-1.0-0.79-0.970.02-0.780.690.140.14
-0.56-0.33-0.940.53-0.05-0.86-0.31-0.17-0.56-0.1-0.33-0.17-0.080.830.590.59
0.450.540.14-0.48-0.05-0.150.55-0.290.450.840.55-0.290.84-0.410.320.32
0.280.030.7-0.24-0.86-0.150.020.220.28-0.210.040.22-0.22-0.75-0.48-0.48
0.961.00.57-0.97-0.310.550.02-0.070.960.871.0-0.070.87-0.530.040.04
0.02-0.080.130.02-0.17-0.290.22-0.070.02-0.12-0.081.0-0.12-0.05-0.34-0.34
1.00.960.78-1.0-0.560.450.280.960.020.750.960.020.74-0.71-0.21-0.21
0.750.870.32-0.79-0.10.84-0.210.87-0.120.750.87-0.121.0-0.380.280.28
0.961.00.59-0.97-0.330.550.041.0-0.080.960.87-0.080.86-0.540.020.02
0.02-0.080.130.02-0.17-0.290.22-0.071.00.02-0.12-0.08-0.12-0.05-0.34-0.34
0.740.860.3-0.78-0.080.84-0.220.87-0.120.741.00.86-0.12-0.360.30.3
-0.72-0.54-0.830.690.83-0.41-0.75-0.53-0.05-0.71-0.38-0.54-0.05-0.360.390.39
-0.210.02-0.610.140.590.32-0.480.04-0.34-0.210.280.02-0.340.30.391.0
-0.210.02-0.610.140.590.32-0.480.04-0.34-0.210.280.02-0.340.30.391.0
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

As per the company's disclosures, Virpax Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Virpax Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virpax Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics of similar companies.
Virpax Pharmaceuticals is currently under evaluation in z score category among its peers.

Virpax Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Virpax Pharmaceuticals from analyzing Virpax Pharmaceuticals' financial statements. These drivers represent accounts that assess Virpax Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Virpax Pharmaceuticals' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap32.3M40.2M7.3M3.7M4.3M4.1M
Enterprise Value33.8M3.3M(11.7M)(5.4M)(6.2M)(5.9M)

Virpax Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Virpax Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Virpax Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Virpax Pharmaceuticals' value.
Shares
Garden State Investment Advisory Services Llc2024-09-30
57.3 K
Wells Fargo & Co2024-06-30
0.0
Citadel Advisors Llc2024-09-30
31.4 K
Geode Capital Management, Llc2024-09-30
28 K
Ubs Group Ag2024-09-30
20.4 K
Two Sigma Securities, Llc2024-09-30
12.5 K
Tower Research Capital Llc2024-09-30
3.8 K
Signature Resources Capital Management, Llc2024-09-30
50.0
Bank Of America Corp2024-09-30
37.0
Morgan Stanley - Brokerage Accounts2024-09-30
15.0
Hantz Financial Services, Inc.2024-09-30
10.0

Virpax Fundamentals

About Virpax Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Virpax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virpax Stock Analysis

When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.